Workflow
b
icon
搜索文档
哈萨克斯坦专家:依托上合组织 中国是维护地区繁荣稳定重要力量 | 世界观·上合
中国新闻网· 2025-07-09 20:10
The "Global Mayors' Dialogue·SCO Summit Cities" event was held in Tianjin on Tuesday. Gulnar Shaimergenova, director of the China Studies Center in Kazakhstan, said in an exclusive interview with China News Network that China plays a vital role in promoting regional security, cooperation, and shared development through multilateral platforms such as the Belt and Road Initiative (BRI) and the Shanghai Cooperation Organization (SCO). 7月8日,"世界市长对话·上合峰会城市"活动在天津举行。哈萨克斯坦中国研究中心主任古丽娜尔·沙伊梅 尔格诺娃(Gulnar Shaimergenova) ...
Ontex introduces lower-carbon bio-based absorbent material in diapers
Globenewswire· 2025-07-09 20:07
Aalst, Belgium, July 9, 2025 – Ontex Group NV [EURONEXT: ONTEX], a leading international developer and producer of personal care solutions, is advancing its sustainability journey with the introduction of bio-based superabsorbent polymers (bioSAP) in its diapers, with an initial rollout in selected Moltex Pure and Nature products. This new material will gradually and incrementally replace virgin fossil-based plastic SAP in the core absorbent component, helping lower the carbon footprint of the product while ...
New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials
Globenewswire· 2025-07-09 20:05
Article Indicates that Inhibition of PP2A Enhances Immunotherapy Responsewith LIXTE’s Proprietary Compound LB100 PASADENA, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that the medical journal Nature has published findings by a team of physician-scientists that validate LIXTE’s ongoing clinical trials with its proprietary compound LB100 for Ovarian and Colorectal canc ...
Despite 2 Scary Words - Bitcoin And Diversification, I'm A Riot Platforms Fan
Seeking Alpha· 2025-07-09 20:00
After 43+ years working for one investment research company or another, I finally retired. So now, I’m completely independent. And for the first time on Seeking Alpha, I won’t be working based on anybody else’s product agenda. I have only one goal now… to give you the best actionable investment insights I can.I have long specialized in rules/factor-based equity investing strategies. But I’m different from others who share such backgrounds. I don’t serve the numbers. Instead, the numbers serve me… to inspire ...
Upwork Research Reveals New Insights Into the AI-Human Work Dynamic
GlobeNewswire News Room· 2025-07-09 20:00
PALO ALTO, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Upwork Inc. (Nasdaq: UPWK), the world’s work marketplace, today released a study by the Upwork Research Institute revealing that AI is not just accelerating productivity, but also moving from being a tool to a teammate, reshaping how organizations design roles, build teams, and sustain human connection in the workplace. The findings show that productivity gains are only sustainable when AI augments, not replaces, human connection, purpose, and growth. The ...
U Power Signs an MOU with NV Gotion to Supply Swapping-Enabled EV Batteries and Develop Battery-Bank Solutions for Thailand and the Broader ASEAN Markets
Prnewswire· 2025-07-09 20:00
SHANGHAI, July 9, 2025 /PRNewswire/ -- U Power Limited (Nasdaq: UCAR) (the "Company" or "U Power"), a provider of comprehensive electric vehicle ("EV") battery-swapping solutions on track of becoming a smart energy grid solutions provider, today announced the signing of a Memorandum of Understanding (the "MOU") with NV Gotion Co., LTD ("NV Gotion"), a globally recognized leader in new energy battery manufacturing, to deploy swapping-enabled EV batteries, and develop battery-bank solutions for compatible EVs ...
Arrowhead Pharmaceuticals (ARWR) 2015 Earnings Call Presentation
2025-07-09 19:34
业绩总结 - ARC-520在84名接受单剂量治疗的人类中未出现严重不良事件,且无因不良事件而中断治疗的情况[16] - ARC-520在HBeAg阳性患者中,单剂量4mg/kg的HBsAg最大降低达到99%(1.9 log),为人类使用RNAi的最高记录[20] - ARC-520的临床数据表明其在不同患者群体中的有效性,尤其是在高cccDNA患者中[26] 用户数据 - 在NUC-naïve HBeAg阳性患者中,HBsAg的平均最大降低为1.05 log,最高达到99%(1.9 log)[21] - 在美国,95%的慢性HBV患者为NUC-naïve,而在西欧则为90%[25] - HBeAg阳性猩猩的HBsAg平均降低达到99%(2.1 log10),而HBeAg阴性猩猩的HBsAg平均降低为81%(0.7 log10)[67] 新产品和新技术研发 - 公司计划在2016年中期提交ARC-521的IND申请,作为ARC-520的补充[30] - 新产品ARC-521正在GMP生产中,预计将在2016年中期开始临床研究,旨在更有效地针对整合HBV DNA衍生的HBsAg[106] - ARC-520的技术在临床中首次验证,显示出深度降低目标mRNA的能力[103] 市场扩张和并购 - 公司已启动ARC-520的多剂量P2b研究,并计划与ARC-520进行组合研究[154] - 公司计划在AASLD会议上展示黑猩猩数据,包括1个海报和1个口头报告[154] 未来展望 - ARC-520预计将作为多剂量疗法进行临床应用,初步数据表明即使在低cccDNA患者中也能显著干扰正常病毒功能[27] - HBeAg阴性患者的先前治疗时间范围为2-8年,且中位数为5年,预计cccDNA浓度已降低至不可检测水平[97] - ARC-521的IND或同等申请预计在2016年5月提交[154] 负面信息 - HBeAg阴性患者的HBV DNA中,cccDNA仅占5%,而HBeAg阳性患者的cccDNA占比显著更高,差异达到500倍[71] - 随着时间推移和NUC治疗,cccDNA水平下降,整合DNA成为HBsAg生产的重要来源[153]
FTI Consulting Expands Export Controls, Sanctions and Trade Practice with Appointment of Two Industry Leaders
Globenewswire· 2025-07-09 19:30
WASHINGTON, July 09, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Eva Tomlinson as a Senior Managing Director and Breck Heidlberg as a Managing Director in the Export Controls, Sanctions and Trade practice within the Forensic and Litigation Consulting segment. Ms. Tomlinson and Mr. Heidlberg bring more than 40 years of combined expertise in global trade strategy, regulatory compliance and national security guidance, deepening FTI Consulting’s capabilities to l ...
Theratechnologies Reports Financial Results for the Second Quarter 2025
Globenewswire· 2025-07-09 19:30
Q2 2025 total revenue of $17.7 million, and $36.8 million for the first six months of Fiscal 2025Positive Adjusted EBITDA1 for the fifth straight quarterSubsequent to quarter end, Theratechnologies entered into a definitive agreement to be acquired by an affiliate of Future Pak MONTREAL, July 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today reported business highlights and financial result ...